Ontology highlight
ABSTRACT:
INSTRUMENT(S): Illumina NovaSeq 6000
ORGANISM(S): Homo sapiens
SUBMITTER: Jani Huuhtanen
PROVIDER: E-MTAB-12733 | biostudies-arrayexpress |
REPOSITORIES: biostudies-arrayexpress
Huuhtanen Jani J Kasanen Henna H Peltola Katriina K Lönnberg Tapio T Glumoff Virpi V Brück Oscar O Dufva Olli O Peltonen Karita K Vikkula Johanna J Jokinen Emmi E Ilander Mette M Lee Moon Hee MH Mäkelä Siru S Nyakas Marta M Li Bin B Hernberg Micaela M Bono Petri P Lähdesmäki Harri H Kreutzman Anna A Mustjoki Satu S
The Journal of clinical investigation 20230315 6
BackgroundRelatlimab plus nivolumab (anti-lymphocyte-activation gene 3 plus anti-programmed death 1 [anti-LAG-3+anti-PD-1]) has been approved by the FDA as a first-line therapy for stage III/IV melanoma, but its detailed effect on the immune system is unknown.MethodsWe evaluated blood samples from 40 immunotherapy-naive or prior immunotherapy-refractory patients with metastatic melanoma treated with anti-LAG-3+anti-PD-1 in a phase I trial using single-cell RNA and T cell receptor sequencing (scR ...[more]